Darifenacin | Suppliers | Impurities | Impurity Standards| PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login

Darifenacin
Others

Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

Contact Supplier

Jai Radhe Sales is your partner for all your sourcing needs.

Contact Supplier

xyz-pharma-m-2024-10-07

Contact Supplier

Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

Contact Supplier

Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

Contact Supplier

xyz-pharma-m-2024-10-07

Contact Supplier

Darifenacin

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

27 API Suppliers, 15 USDMF, 9 EU WC, 7 NDC API, 15 Listed Suppliers, $ API Reference Price

27 API Suppliers
15 USDMF
9 EU WC
7 NDC API
15 Listed Suppliers
$ API Reference Price

INTERMEDIATES

8 Intermediates Suppliers

8 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

55 FDF Dossiers, 20 FDA Orange Book, 14 Europe, 6 Canada, 5 South Africa, 10 Listed Dossiers

55 FDF Dossiers
20 FDA Orange Book
14 Europe
6 Canada
5 South Africa
10 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET, EXTENDED RELEASE;ORAL - EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, EXTENDED RELEASE;ORAL - EQ 7.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, EXTENDED RELEASE;ORAL - EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET, EXTENDED RELEASE;ORAL - EQ 7.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

1 SPI Pharma, 2 Seqens, 3 DKSH, 2 Faran Shimi Pharmaceutical, 3 Boai NKY Pharmaceuticals Ltd, 8 Gangwal Healthcare, 5 Nanjing Well Pharmaceutical, 1 ACG Worldwide, 3 Actylis, 1 Aeon Procare, 4 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 1 Avesta Pharma, 9 BASF, 3 Clariant, 10 Corel Pharma Chem, 4 DFE Pharma, 1 Finar, 8 Gangwal Chemicals, 7 Ideal Cures Pvt Ltd, 31 Kerry, 3 Kima Chemical, 6 Lonza Capsugel, 10 Microlex e.U, 2 Nomisma Healthcare, 2 Novo Excipients, 1 Pharmatrans-Sanaq, 2 Pluviaendo, 2 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 9 Roquette, 6 Seppic, 4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 10 Sigachi Industries, 2 The Dow Chemical Company, 1 Ulanqab Kema New Material, 2 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

50 Fillers, Diluents & Binders, 50 Coating Systems & Additives, 28 Controlled & Modified Release, 20 Direct Compression, 18 Thickeners and Stabilizers, 17 Lubricants & Glidants, 14 Topical, 13 Co-Processed Excipients, 11 Film Formers & Plasticizers, 11 Granulation, 8 Solubilizers, 7 Disintegrants & Superdisintegrants, 7 Parenteral, 6 API Stability Enhancers, 5 Empty Capsules, 5 Emulsifying Agents, 4 Vegetarian Capsules, 4 Taste Masking, 4 Coloring Agents, 3 Rheology Modifiers, 3 Chewable & Orodispersible Aids, 2 Surfactant & Foaming Agents

50 Fillers, Diluents & Binders
50 Coating Systems & Additives
28 Controlled & Modified Release
20 Direct Compression
18 Thickeners and Stabilizers
17 Lubricants & Glidants
14 Topical
13 Co-Processed Excipients
11 Film Formers & Plasticizers
11 Granulation
8 Solubilizers
7 Disintegrants & Superdisintegrants
7 Parenteral
6 API Stability Enhancers
5 Empty Capsules
5 Emulsifying Agents
4 Vegetarian Capsules
4 Taste Masking
4 Coloring Agents
3 Rheology Modifiers
3 Chewable & Orodispersible Aids
2 Surfactant & Foaming Agents

DIGITAL CONTENT

12 NEWS #PharmaBuzz

12 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

10 Finished Drug Prices, 2 Annual Reports

10 Finished Drug Prices
2 Annual Reports

MARKET PLACE

2 APIs, 4 FDF Dossiers

2 APIs
4 FDF Dossiers

PATENTS & EXCLUSIVITIES

8 Health Canada Patents

8 Health Canada Patents

REF. STANDARDS & IMPURITIES

3 USP, 4 Others

3 USP
4 Others

ANALYTICAL

1 BioAnalytical Methods

1 BioAnalytical Methods

$ API Ref.Price (USD/KG) : 4,535 Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Name Reset all filters

4 All

01 1Creative Peptides

02 3USP

filter CAS Number Reset all filters

4 All

01 1133099-04-4

02 1133099-07-7

03 2Blank

filter Details Reset all filters

4 All

01 1Darifenacin hydrobromide is used to treat people who have urinary problems such as urinary incontinence, urinary urgency or urinary frequency which are caused by an overactive bladder. It works by preventing spasms of the bladder?muscle. This can help to reduce the episodes of urinary incontinence, the frequency of urination or reduce the feeling of urgency that bladder spasms can cause. More information please visit the website: http://www.creative-peptides.com/product/darifenacin-hydrobromide-

02 3Material Origin- Chemical Synthesis; USMCA- No; KORUS- No

filter Country Reset all filters

4 All

01 4U.S.A

Product Main Page

01

Creative Peptides

CPhI India 2024

Not Confirmed

Creative Peptides

CPhI India 2024

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

Post an Enquiry

Digital Content

Darifenacin Hydrobromide

CAS Number : 133099-04-4

Quantity Per Vial :

Sale Unit :

Price :

Details : Darifenacin hydrobromide is used to treat peo...

Monograph :

Storage :

Code/Batch No : 10-101-114

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

USP

CPhI India 2024

Not Confirmed

USP

CPhI India 2024

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

Post an Enquiry

Digital Content

Darifenacin Chiral Peak ID Mixture (25 mg) (S...

CAS Number :

Quantity Per Vial : 25

Sale Unit : mg

Price : $581.25

Details : Material Origin- Chemical Synthesis; USMCA- N...

Monograph :

Storage :

Code/Batch No : Catalog #1164211 / F04970

Product Web Link

Digital Content

03

USP

CPhI India 2024

Not Confirmed

USP

CPhI India 2024

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

Post an Enquiry

Digital Content

Darifenacin Peak ID Mixture (25 mg) (A mixtur...

CAS Number :

Quantity Per Vial : 25

Sale Unit : mg

Price : $547.50

Details : Material Origin- Chemical Synthesis; USMCA- N...

Monograph :

Storage :

Code/Batch No : Catalog #1164222 / F04980

Product Web Link

Digital Content

04

USP

CPhI India 2024

Not Confirmed

USP

CPhI India 2024

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

Post an Enquiry

Digital Content

Darifenacin Hydrobromide (150 mg)

CAS Number : 133099-07-7

Quantity Per Vial : 150

Sale Unit : mg

Price : $585.00

Details : Material Origin- Chemical Synthesis; USMCA- N...

Monograph :

Storage :

Code/Batch No : Catalog #1164200 / F04960

Product Web Link

Digital Content

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
LOOKING FOR A SUPPLIER?